These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34016557)

  • 21. Identification of exhaled volatile organic compounds that characterize asthma phenotypes: A J-VOCSA study.
    Suzukawa M; Ohta K; Sugimoto M; Ohshima N; Kobayashi N; Tashimo H; Tanimoto Y; Itano J; Kimura G; Takata S; Nakano T; Yamashita T; Ikegame S; Hyodo K; Abe M; Chibana K; Kamide Y; Sasaki K; Hashimoto H
    Allergol Int; 2024 Oct; 73(4):524-531. PubMed ID: 38658257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can exhaled volatile organic compounds predict asthma exacerbations in children?
    van Vliet D; Smolinska A; Jöbsis Q; Rosias P; Muris J; Dallinga J; Dompeling E; van Schooten FJ
    J Breath Res; 2017 Mar; 11(1):016016. PubMed ID: 28102830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Volatile organic compounds in exhaled breath are independent of systemic inflammatory syndrome caused by intravenous lipopolysaccharide infusion in humans: results from an experiment in healthy volunteers.
    Peters AL; Gerritsen MG; Brinkman P; Zwinderman KAH; Vlaar APJ; Bos LD
    J Breath Res; 2017 Apr; 11(2):026003. PubMed ID: 28397711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa Volatilome Characteristics and Adaptations in Chronic Cystic Fibrosis Lung Infections.
    Davis TJ; Karanjia AV; Bhebhe CN; West SB; Richardson M; Bean HD
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33028687
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review.
    van de Kant KD; van der Sande LJ; Jöbsis Q; van Schayck OC; Dompeling E
    Respir Res; 2012 Dec; 13(1):117. PubMed ID: 23259710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening.
    Hayes D; Farrell PM; Li Z; West SE
    Pediatr Pulmonol; 2010 Jan; 45(1):55-61. PubMed ID: 20025049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease.
    Pizzini A; Filipiak W; Wille J; Ager C; Wiesenhofer H; Kubinec R; Blaško J; Tschurtschenthaler C; Mayhew CA; Weiss G; Bellmann-Weiler R
    J Breath Res; 2018 Mar; 12(3):036002. PubMed ID: 29295966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro volatile organic compound profiling using GC×GC-TOFMS to differentiate bacteria associated with lung infections: a proof-of-concept study.
    Nizio KD; Perrault KA; Troobnikoff AN; Ueland M; Shoma S; Iredell JR; Middleton PG; Forbes SL
    J Breath Res; 2016 Apr; 10(2):026008. PubMed ID: 27120170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pseudomonas aeruginosa and Burkholderia cepacia cannot be detected by PCR in the breath condensate of patients with cystic fibrosis.
    Vogelberg C; Hirsch T; Rösen-Wolff A; Kerkmann ML; Leupold W
    Pediatr Pulmonol; 2003 Oct; 36(4):348-52. PubMed ID: 12950050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exhaled volatile organic compounds detect pulmonary exacerbations early in children with cystic fibrosis: results of a 1 year observational pilot study.
    van Horck M; Smolinska A; Wesseling G; de Winter-de Groot K; de Vreede I; Winkens B; Jöbsis Q; Dallinga J; Dompeling E; van Schooten FJ
    J Breath Res; 2021 Feb; 15(2):026012. PubMed ID: 33630756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Pseudomonas aeruginosa and Aspergillus fumigatus mono- and co-cultures based on volatile biomarker combinations.
    Neerincx AH; Geurts BP; Habets MFJ; Booij JA; van Loon J; Jansen JJ; Buydens LMC; van Ingen J; Mouton JW; Harren FJM; Wevers RA; Merkus PJFM; Cristescu SM; Kluijtmans LAJ
    J Breath Res; 2016 Jan; 10(1):016002. PubMed ID: 26824272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteria in the airways of patients with cystic fibrosis are genetically capable of producing VOCs in breath.
    Bos LD; Meinardi S; Blake D; Whiteson K
    J Breath Res; 2016 Dec; 10(4):047103. PubMed ID: 27991430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis.
    Enderby B; Smith D; Carroll W; Lenney W
    Pediatr Pulmonol; 2009 Feb; 44(2):142-7. PubMed ID: 19148935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profiling of volatile organic compounds in exhaled breath as a strategy to find early predictive signatures of asthma in children.
    Smolinska A; Klaassen EM; Dallinga JW; van de Kant KD; Jobsis Q; Moonen EJ; van Schayck OC; Dompeling E; van Schooten FJ
    PLoS One; 2014; 9(4):e95668. PubMed ID: 24752575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exhaled breath and urinary volatile organic compounds (VOCs) for cancer diagnoses, and microbial-related VOC metabolic pathway analysis: a systematic review and meta-analysis.
    Zhou M; Wang Q; Lu X; Zhang P; Yang R; Chen Y; Xia J; Chen D
    Int J Surg; 2024 Mar; 110(3):1755-1769. PubMed ID: 38484261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.
    Reece E; Segurado R; Jackson A; McClean S; Renwick J; Greally P
    BMC Pulm Med; 2017 Apr; 17(1):70. PubMed ID: 28431569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.
    Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K
    Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva.
    Amann A; Costello Bde L; Miekisch W; Schubert J; Buszewski B; Pleil J; Ratcliffe N; Risby T
    J Breath Res; 2014 Sep; 8(3):034001. PubMed ID: 24946087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stable isotope profiles reveal active production of VOCs from human-associated microbes.
    Phan J; Meinardi S; Barletta B; Blake DR; Whiteson K
    J Breath Res; 2017 Feb; 11(1):017101. PubMed ID: 28070022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.